Brookfield Infrastructure has an attractive yield and an attractive business to offer long-term income investors.
4D Molecular Therapeutics trades below its cash balance, offering significant upside as its late-stage gene therapy programs advance. FDMT's lead asset, 4D-150, targets wet AMD and DME, with Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback